{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:05:35Z","timestamp":1793862335991,"version":"4.6.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11154-020-09595-0","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T21:51:03Z","timestamp":1600811463000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Laron syndrome \u2013 A historical perspective"],"prefix":"10.1007","volume":"22","author":[{"given":"Zvi","family":"Laron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"issue":"3","key":"9595_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1210\/jc.2003-031033","volume":"89","author":"Z Laron","year":"2004","unstructured":"Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab. 2004;89(3):1031\u201344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9595_CR2","first-page":"269","volume":"12","author":"Z Laron","year":"1980","unstructured":"Laron Z, Kowadlo-Silbergeld A, Eshet R, Pertzelan A. Growth hormone resistance. Ann Clin Res. 1980;12(5):269\u201377.","journal-title":"Ann Clin Res"},{"key":"9595_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/199784a0","volume":"199","author":"SM Glick","year":"1963","unstructured":"Glick SM, Roth J, Yalow RS, Berson SA. Immunoassay of human growth hormone in plasma. Nature. 1963;199:784\u20137.","journal-title":"Nature."},{"issue":"1","key":"9595_CR4","first-page":"115","volume":"2","author":"Z Laron","year":"1966","unstructured":"Laron Z, Mannheimer S. Measurement of human growth hormone. Description of the method and its clinical applications. Isr J Med Sci. 1966;2(1):115\u20139.","journal-title":"Isr J Med Sci"},{"issue":"2","key":"9595_CR5","first-page":"152","volume":"2","author":"Z Laron","year":"1966","unstructured":"Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone-a new inborn error of metabolism? Isr J Med Sci. 1966;2(2):152\u20135.","journal-title":"Isr J Med Sci"},{"issue":"4","key":"9595_CR6","first-page":"883","volume":"4","author":"Z Laron","year":"1968","unstructured":"Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci. 1968;4(4):883\u201394.","journal-title":"Isr J Med Sci"},{"issue":"2","key":"9595_CR7","first-page":"75","volume":"24","author":"R Keret","year":"1988","unstructured":"Keret R, Pertzelan A, Zeharia A, Zadik Z, Laron Z. Growth hormone (hGH) secretion and turnover in three patients with Laron-type dwarfism. Isr J Med Sci. 1988;24(2):75\u20139.","journal-title":"Isr J Med Sci"},{"issue":"1","key":"9595_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF00441167","volume":"137","author":"A Adam","year":"1981","unstructured":"Adam A, Josefsberg Z, Pertzelan A, Zadik Z, Chemke JM, Laron Z. Occurrence of four types of growth hormone-related dwarfism in Israeli communities. Eur J Pediatr. 1981;137(1):35\u20139.","journal-title":"Eur J Pediatr"},{"issue":"7561","key":"9595_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0140-6736(68)92623-8","volume":"2","author":"TJ Merimee","year":"1968","unstructured":"Merimee TJ, Hall J, Rabinowitz D, McKusick VA, Rimoin DL. An unusual variety of endocrine dwarfism: subresponsiveness to growth hormone in a sexually mature dwarf. Lancet. 1968;2(7561):191\u20133.","journal-title":"Lancet."},{"issue":"4","key":"9595_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1651-2227.1975.tb03891.x","volume":"64","author":"KW Kastrup","year":"1975","unstructured":"Kastrup KW, Andersen H, Hanssen AF. Increased immunoreactive plasma and urinary growth hormone in growth retardation with defective generation of somatomedin a (Laron's syndrome). Acta Paediatr Scand. 1975;64(4):613\u20138.","journal-title":"Acta Paediatr Scand"},{"issue":"15","key":"9595_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJM197104152841502","volume":"284","author":"SS Najjar","year":"1971","unstructured":"Najjar SS, Khachadurian AK, Ilbawi MN, Blizzard RM. Dwarfism with elevated levels of plasma growth hormone. N Engl J Med. 1971;284(15):809\u201312.","journal-title":"N Engl J Med"},{"issue":"2","key":"9595_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0022-3476(73)80485-8","volume":"83","author":"MJ Elders","year":"1973","unstructured":"Elders MJ, Garland JT, Daughaday WA, Fisher DA, Whitney JE, Hughes ER. Laron's dwarfism: studies on the nature of the defect. J Pediatr. 1973;83(2):253\u201363.","journal-title":"J Pediatr"},{"issue":"5","key":"9595_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1210\/jcem-37-5-819","volume":"37","author":"R Eshet","year":"1973","unstructured":"Eshet R, Laron Z, Brown M, Arnon R. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J Clin Endocrinol Metab. 1973;37(5):819\u201321.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9595_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000180106","volume":"22","author":"R Eshet","year":"1985","unstructured":"Eshet R, Peleg S, Josefsberg Z, Fuchs C, Arnon R, Laron Z. Some properties of the plasma hGH activity in patients with Laron-type dwarfism determined by a radio receptor assay using human liver tissue. Horm Res. 1985;22(4):276\u201383.","journal-title":"Horm Res"},{"issue":"6","key":"9595_CR15","first-page":"342","volume":"25","author":"RE Russell","year":"1989","unstructured":"Russell RE, Parks JS, McKean MC, Bell GI, Keret R, Kelijman M, et al. Laron-type dwarfism is associated with normal growth hormone and insulin-like growth factor I gene restriction patterns. Isr J Med Sci. 1989;25(6):342\u20134.","journal-title":"Isr J Med Sci"},{"issue":"4","key":"9595_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1055\/s-0028-1095565","volume":"9","author":"Z Laron","year":"1977","unstructured":"Laron Z, Pertzelan A, Doron M, Assa S, Keret R. The effect of dihydrosomatostatin in dwarfism with high plasma immunoreactive growth hormone. Horm Metab Res. 1977;9(4):338\u20139.","journal-title":"Horm Metab Res"},{"key":"9595_CR17","first-page":"129","volume":"82","author":"WH Daughaday","year":"1969","unstructured":"Daughaday WH, Laron Z, Pertzelan A, Heins JN. Defective sulfation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Phys. 1969;82:129\u201340.","journal-title":"Trans Assoc Am Phys"},{"issue":"2","key":"9595_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1210\/jcem-33-2-332","volume":"33","author":"Z Laron","year":"1971","unstructured":"Laron Z, Pertzelan A, Karp M, Kowadlo-Silbergeld A, Daughaday WH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone: measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol Metab. 1971;33(2):332\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9595_CR19","first-page":"8","volume":"20","author":"R Eshet","year":"1984","unstructured":"Eshet R, Laron Z, Pertzelan A, Arnon R, Dintzman M. Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci. 1984;20(1):8\u201311.","journal-title":"Isr J Med Sci"},{"issue":"5","key":"9595_CR20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1210\/jcem-64-5-1042","volume":"64","author":"ME Geffner","year":"1987","unstructured":"Geffner ME, Golde DW, Lippe BM, Kaplan SA, Bersch N, Li CH. Tissues of the Laron dwarf are sensitive to insulin-like growth factor I but not to growth hormone. J Clin Endocrinol Metab. 1987;64(5):1042\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"9595_CR21","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM198011133032006","volume":"303","author":"DW Golde","year":"1980","unstructured":"Golde DW, Bersch N, Kaplan SA, Rimoin DL, Li CH. Peripheral unresponsiveness to human growth hormone in Laron dwarfism. N Engl J Med. 1980;303(20):1156\u20139.","journal-title":"N Engl J Med"},{"key":"9595_CR22","doi-asserted-by":"crossref","unstructured":"Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z. Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci U S A 1989;86(20):8083\u20138087.","DOI":"10.1073\/pnas.86.20.8083"},{"issue":"5","key":"9595_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1530\/eje.0.1500635","volume":"150","author":"A Besson","year":"2004","unstructured":"Besson A, Salemi S, Eble A, Joncourt F, Gallati S, Jorge AA, et al. Primary GH insensitivity (Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur J Endocrinol. 2004;150(5):635\u201342.","journal-title":"Eur J Endocrinol"},{"issue":"15","key":"9595_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJM198910123211501","volume":"321","author":"S Amselem","year":"1989","unstructured":"Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, et al. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med. 1989;321(15):989\u201395.","journal-title":"N Engl J Med"},{"issue":"3","key":"9595_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0022-3476(99)70121-6","volume":"135","author":"AL Rosenbloom","year":"1999","unstructured":"Rosenbloom AL. Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. J Pediatr. 1999;135(3):280\u20139.","journal-title":"J Pediatr"},{"issue":"Suppl 3","key":"9595_CR26","first-page":"489","volume":"3","author":"O Shevah","year":"2006","unstructured":"Shevah O, Laron Z. Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome. Pediatr Endocrinol Rev. 2006;3(Suppl 3):489\u201397.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"2","key":"9595_CR27","first-page":"435","volume":"82","author":"ML Sobrier","year":"1997","unstructured":"Sobrier ML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, et al. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. J Clin Endocrinol Metab. 1997;82(2):435\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9595_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2265.2004.01930.x","volume":"60","author":"AA Jorge","year":"2004","unstructured":"Jorge AA, Souza SC, Arnhold IJ, Mendonca BB. The first homozygous mutation (S226I) in the highly-conserved WSXWS-like motif of the GH receptor causing Laron syndrome: supression of GH secretion by GnRH analogue therapy not restored by dihydrotestosterone administration. Clin Endocrinol. 2004;60(1):36\u201340.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"9595_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1515\/JPEM.1997.10.3.265","volume":"10","author":"A Silbergeld","year":"1997","unstructured":"Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, et al. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab. 1997;10(3):265\u201374.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"9595_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.14148","volume":"92","author":"A Rughani","year":"2020","unstructured":"Rughani A, Zhang D, Vairamani K, Dauber A, Hwa V, Krishnan S. Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein. Clin Endocrinol. 2020;92(4):331\u20137.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"9595_CR31","first-page":"54","volume":"76","author":"K Kou","year":"1993","unstructured":"Kou K, Lajara R, Rotwein P. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. J Clin Endocrinol Metab. 1993;76(1):54\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9595_CR32","first-page":"531","volume":"83","author":"K Iida","year":"1998","unstructured":"Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, et al. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab. 1998;83(2):531\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"9595_CR33","first-page":"3705","volume":"82","author":"H Kaji","year":"1997","unstructured":"Kaji H, Nose O, Tajiri H, Takahashi Y, Iida K, Takahashi T, et al. Novel compound heterozygous mutations of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab. 1997;82(11):3705\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9595_CR34","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1210\/jc.2006-2624","volume":"92","author":"P Fang","year":"2007","unstructured":"Fang P, Riedl S, Amselem S, Pratt KL, Little BM, Haeusler G, et al. Primary growth hormone (GH) insensitivity and insulin-like growth factor deficiency caused by novel compound heterozygous mutations of the GH receptor gene: genetic and functional studies of simple and compound heterozygous states. J Clin Endocrinol Metab. 2007;92(6):2223\u201331.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9595_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ajpa.20655","volume":"134","author":"I Hershkovitz","year":"2007","unstructured":"Hershkovitz I, Kornreich L, Laron Z. Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity (Laron syndrome). Am J Phys Anthropol. 2007;134(2):198\u2013208.","journal-title":"Am J Phys Anthropol"},{"key":"9595_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1525\/9780520949645","volume-title":"The Fossil Chronicles","author":"D Falk","year":"2011","unstructured":"Falk D. The Fossil Chronicles. Berkeley: University of California Press; 2011. p. 152\u20135."},{"issue":"7","key":"9595_CR37","first-page":"2554","volume":"83","author":"JL Walker","year":"1998","unstructured":"Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJ, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab. 1998;83(7):2554\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"9595_CR38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.4103\/2230-8210.140236","volume":"18","author":"SR Phanse-Gupte","year":"2014","unstructured":"Phanse-Gupte SR, Khadilkar VV, Khadilkar AV. Clinical features and endocrine profile of Laron syndrome in Indian children. Indian J Endocrinol Metab. 2014;18(6):863\u20137.","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"9595_CR39","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/adc.61.12.1233","volume":"61","author":"ME McGraw","year":"1986","unstructured":"McGraw ME, Price DA, Hill DJ. Somatomedin C deficiency in Asian sisters. Arch Dis Child. 1986;61(12):1233\u20135.","journal-title":"Arch Dis Child"},{"key":"9595_CR40","first-page":"93","volume-title":"Lessons from Laron syndrome (LS) 1966\u20131992","author":"M Razzaghy-Aza","year":"1993","unstructured":"Razzaghy-Aza M. Laron syndrome \u2013 a review of 8 Iranian patients with Laron syndrome. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966\u20131992. Basel: Karger; 1993. p. 93\u2013100."},{"issue":"5","key":"9595_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1530\/eje.0.1330539","volume":"133","author":"N Yordam","year":"1995","unstructured":"Yordam N, Kandemir N, Erkul I, Kurdoglu S, Hatun S. Review of Turkish patients with growth hormone insensitivity (Laron type). Eur J Endocrinol. 1995;133(5):539\u201342.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9595_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.14310\/horm.2002.1191","volume":"2","author":"A Galli-Tsinopoulou","year":"2003","unstructured":"Galli-Tsinopoulou A, Nousia-Arvanitakis S, Tsinopoulos I, Bechlivanides C, Shevah O, Laron Z. Laron syndrome. First report from Greece. Hormones (Athens). 2003;2(2):120\u20134.","journal-title":"Hormones (Athens)"},{"key":"9595_CR43","first-page":"70","volume-title":"Lessons from Laron syndrome (LS) 1966\u20131992","author":"A Cohen","year":"1993","unstructured":"Cohen A, Cordone G, Fasce G, Romano C. An additional patient of Laron \u2013type dwarfism in Italy. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966\u20131992. Basel: Karger; 1993. p. 70\u20132."},{"issue":"2","key":"9595_CR44","first-page":"151","volume":"35","author":"M Pierson","year":"1978","unstructured":"Pierson M, Malaprade D, Fortier G, Belleville F, Lasbennes A, Wuilbereq L. Laron type familial dwarfism; genetic primary somatomedin deficiency. Arch Fr Pediatr. 1978;35(2):151\u201364.","journal-title":"Arch Fr Pediatr"},{"issue":"2","key":"9595_CR45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/jcem-47-2-453","volume":"47","author":"JJ Alcaniz","year":"1978","unstructured":"Alcaniz JJ, Salto L, Barcelo B. GH secretion in two siblings with Laron's dwarfism: the effects of glucose, arginine, somatostatin, and bromocryptine. J Clin Endocrinol Metab. 1978;47(2):453\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"9595_CR46","first-page":"444","volume":"82","author":"L Baumbach","year":"1997","unstructured":"Baumbach L, Schiavi A, Bartlett R, Perera E, Day J, Brown MR, et al. Clinical, biochemical, and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). J Clin Endocrinol Metab. 1997;82(2):444\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"9595_CR47","first-page":"73","volume-title":"Lessons from Laron syndrome (LS) 1966\u20131992","author":"G Costin","year":"1993","unstructured":"Costin G, Roe T, Clemons R, Kogut M. Growth hormone resistance syndrome (Laron-type dwarfism). In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966\u20131992. Basel: Karger; 1993. p. 73\u201380."},{"issue":"20","key":"9595_CR48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJM199011153232002","volume":"323","author":"AL Rosenbloom","year":"1990","unstructured":"Rosenbloom AL, Guevara Aguirre J, Rosenfeld RG, Fielder PJ. The little women of Loja--growth hormone-receptor deficiency in an inbred population of southern Ecuador. N Engl J Med. 1990;323(20):1367\u201374.","journal-title":"N Engl J Med"},{"issue":"4","key":"9595_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF00295474","volume":"59","author":"PH Saldanha","year":"1981","unstructured":"Saldanha PH, Toledo SP. Familial dwarfism with high IR-GH: report of two affected sibs with genetic and epidemiologic considerations. Hum Genet. 1981;59(4):367\u201372.","journal-title":"Hum Genet"},{"issue":"3","key":"9595_CR50","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1590\/S0004-27302005000300009","volume":"49","author":"AA de Lima Jorge","year":"2005","unstructured":"de Lima Jorge AA, de Menezes Filho HC, Soares Lins TS, Guedes DR, Damiani D, Setian N, et al. Efeito fundador la mutacao E180splice no Gene do Receptor de Hormonio de Crescimento Identificada em Pacientes Brasileiros Com Insensibilidade ao GH. Arq Bras Endocinol Metab. 2005;49(3):384\u20139.","journal-title":"Arq Bras Endocinol Metab"},{"key":"9595_CR51","first-page":"101","volume-title":"Lessons from Laron syndrome (LS) 1966\u20131992","author":"MC Arriazu","year":"1993","unstructured":"Arriazu MC, Gonzalez A. The first reported case of Laron \u2013type dwarfism in Argentina. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966\u20131992. Basel: Karger; 1993. p. 101\u20133."},{"issue":"5","key":"9595_CR52","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/ajmg.a.36444","volume":"164A","author":"FT Goncalves","year":"2014","unstructured":"Goncalves FT, Fridman C, Pinto EM, Guevara-Aguirre J, Shevah O, Rosembloom AL, et al. The E180splice mutation in the GHR gene causing Laron syndrome: witness of a Sephardic Jewish exodus from the Iberian Peninsula to the New World? Am J Med Genet A. 2014;164A(5):1204\u20138.","journal-title":"Am J Med Genet A"},{"key":"9595_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-642-11183-9_4","volume-title":"Laron syndrome from man to mouse","author":"Z Laron","year":"2011","unstructured":"Laron Z. Diagnosis of Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Berlin Heidelberg: Springer Verlag; 2011. p. 27\u20138."},{"key":"9595_CR54","first-page":"3","volume-title":"Lessons from Laron syndrome (LS) 1966\u20131992","author":"Z Laron","year":"1993","unstructured":"Laron Z, Pertzelan A, Karp M, Keret R, Eshet R. Silbergeld. A 1993 Laron syndrome \u2013 a unique model of IGF-I deficiency. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966\u20131992. Basel: Karger; 1993. p. 3\u201323."},{"key":"9595_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-3-642-11183-9_8","volume-title":"Laron Syndrome from Man to Mouse","author":"Z Laron","year":"2011","unstructured":"Laron Z, Kauli R. Linear growth pattern of untreated Laron syndrome patients. In: Laron Z, Kopchick JJ, editors. Laron Syndrome from Man to Mouse. Berlin: Springer Verlag; 2011. p. 63\u201389."},{"issue":"3","key":"9595_CR56","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1515\/JPEM.2009.22.3.235","volume":"22","author":"O Konen","year":"2009","unstructured":"Konen O, Silbergeld A, Lilos P, Kornreich L, Laron Z. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome. J Pediatr Endocrinol Metab. 2009;22(3):235\u20139.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"9595_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-0028-1094075","volume":"4","author":"A Scharf","year":"1972","unstructured":"Scharf A, Laron Z. Skull changes in pituitary dwarfism and the syndrome of familial dwarfism with high plasma immunoreactive growth hormone--a Roentgenologic study. Horm Metab Res. 1972;4(2):93\u20137.","journal-title":"Horm Metab Res"},{"issue":"2","key":"9595_CR58","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/0002-9416(75)90208-0","volume":"68","author":"R Konfino","year":"1975","unstructured":"Konfino R, Pertzelan A, Laron Z. Cephalometric measurements of familial dwarfism and high plasma immunoreactive growth hormone. Am J Orthod. 1975;68(2):196\u2013201.","journal-title":"Am J Orthod"},{"issue":"4","key":"9595_CR59","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1159\/000077839","volume":"208","author":"R Lurie","year":"2004","unstructured":"Lurie R, Ben-Amitai D, Laron Z. Laron syndrome (primary growth hormone insensitivity): a unique model to explore the effect of insulin-like growth factor 1 deficiency on human hair. Dermatology. 2004;208(4):314\u20138.","journal-title":"Dermatology."},{"issue":"7","key":"9595_CR60","doi-asserted-by":"publisher","first-page":"1197.e1191","DOI":"10.1016\/j.ophtha.2005.12.023","volume":"113","author":"DH Bourla","year":"2006","unstructured":"Bourla DH, Laron Z, Snir M, Lilos P, Weinberger D, Axer-Siegel R. Insulin like growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome. Ophthalmology. 2006;113(7):1197.e1191\u20135.","journal-title":"Ophthalmology"},{"key":"9595_CR61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-3-642-11183-9_23","volume-title":"Laron Syndrome from Man to Mouse","author":"Z Laron","year":"2011","unstructured":"Laron Z. The teeth in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron Syndrome from Man to Mouse. Berlin: Springer Verlag; 2011. p. 213\u20137."},{"issue":"2","key":"9595_CR62","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00405-011-1668-x","volume":"269","author":"J Attias","year":"2012","unstructured":"Attias J, Zarchi O, Nageris BI, Laron Z. Cochlear hearing loss in patients with Laron syndrome. Eur Arch Otorhinolaryngol. 2012;269(2):461\u20136.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1\u20133","key":"9595_CR63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000183762","volume":"40","author":"Z Laron","year":"1993","unstructured":"Laron Z, Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm Res. 1993;40(1\u20133):16\u201322.","journal-title":"Horm Res"},{"issue":"1","key":"9595_CR64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1365-2265.2006.02558.x","volume":"65","author":"Z Laron","year":"2006","unstructured":"Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin Endocrinol. 2006;65(1):114\u20137.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"9595_CR65","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ghir.2008.03.003","volume":"18","author":"Z Laron","year":"2008","unstructured":"Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Hormon IGF Res. 2008;18(5):434\u20138.","journal-title":"Growth Hormon IGF Res"},{"issue":"6","key":"9595_CR66","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1530\/EJE-09-0419","volume":"161","author":"H Kanety","year":"2009","unstructured":"Kanety H, Hemi R, Ginsberg S, Pariente C, Yissachar E, Barhod E, et al. Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur J Endocrinol. 2009;161(6):837\u201344.","journal-title":"Eur J Endocrinol"},{"issue":"10 Suppl 4","key":"9595_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0026-0495(95)90231-7","volume":"44","author":"Z Laron","year":"1995","unstructured":"Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism. 1995;44(10 Suppl 4):113\u20138.","journal-title":"Metabolism."},{"issue":"1","key":"9595_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1530\/eje.0.1510103","volume":"151","author":"Z Laron","year":"2004","unstructured":"Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol. 2004;151(1):103\u20136.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9595_CR69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1054\/ghir.2001.0235","volume":"11","author":"Y Dagan","year":"2001","unstructured":"Dagan Y, Abadi J, Lifschitz A, Laron Z. Severe obstructive sleep apnoea syndrome in an adult patient with Laron syndrome. Growth Hormon IGF Res. 2001;11(4):247\u20139.","journal-title":"Growth Hormon IGF Res"},{"issue":"Suppl 1","key":"9595_CR70","first-page":"231","volume":"12","author":"Z Laron","year":"1999","unstructured":"Laron Z. Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). J Pediatr Endocrinol Metab. 1999;12(Suppl 1):231\u201349.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"9595_CR71","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/acta.0.0630625","volume":"63","author":"Z Laron","year":"1970","unstructured":"Laron Z, Sarel R. Penis and testicular size in patients with growth hormone insufficiency. Acta Endocrinol. 1970;63(4):625\u201333.","journal-title":"Acta Endocrinol"},{"issue":"1","key":"9595_CR72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF00442408","volume":"134","author":"Z Laron","year":"1980","unstructured":"Laron Z, Sarel R, Pertzelan A. Puberty in Laron type dwarfism. Eur J Pediatr. 1980;134(1):79\u201383.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"9595_CR73","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0002-9149(99)00642-6","volume":"85","author":"MS Feinberg","year":"2000","unstructured":"Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol. 2000;85(2):209\u201313.","journal-title":"Am J Cardiol"},{"issue":"2","key":"9595_CR74","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000185429","volume":"47","author":"O Brat","year":"1997","unstructured":"Brat O, Ziv I, Klinger B, Avraham M, Laron Z. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome. Horm Res. 1997;47(2):45\u20138.","journal-title":"Horm Res"},{"issue":"6","key":"9595_CR75","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1046\/j.1365-2265.2003.01920.x","volume":"59","author":"I Ben-Dov","year":"2003","unstructured":"Ben-Dov I, Gaides M, Scheinowitz M, Wagner R, Laron Z. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome). Clin Endocrinol. 2003;59(6):763\u20137.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"9595_CR76","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/eje.0.1460499","volume":"146","author":"L Kornreich","year":"2002","unstructured":"Kornreich L, Horev G, Schwarz M, Karmazyn B, Laron Z. Craniofacial and brain abnormalities in Laron syndrome (primary growth hormone insensitivity). Eur J Endocrinol. 2002;146(4):499\u2013503.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9595_CR77","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00256-007-0402-7","volume":"37","author":"L Kornreich","year":"2008","unstructured":"Kornreich L, Konen O, Schwarz M, Siegel Y, Horev G, Hershkovitz I, et al. Abnormalities of the axial and proximal appendicular skeleton in adults with Laron syndrome (growth hormone insensitivity). Skelet Radiol. 2008;37(2):153\u201360.","journal-title":"Skelet Radiol"},{"issue":"10","key":"9595_CR78","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1210\/jc.2003-030623","volume":"88","author":"CA Benbassat","year":"2003","unstructured":"Benbassat CA, Eshed V, Kamjin M, Laron Z. Are adult patients with Laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities. J Clin Endocrinol Metab. 2003;88(10):4586\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"9595_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-642-11183-9_3","volume-title":"Laron Syndrome from Man to Mouse","author":"Z Laron","year":"2011","unstructured":"Laron Z. Clinical evidence of growth hormone resistance in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron Syndrome from Man to Mouse. Berlin: Springer Verlag; 2011. p. 21\u20135."},{"issue":"8621","key":"9595_CR80","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S0140-6736(88)90236-X","volume":"2","author":"Z Laron","year":"1988","unstructured":"Laron Z, Klinger B, Erster B, Anin S. Effect of acute administration of insulin-like growth factor I n patients with Laron-type dwarfism. Lancet. 1988;2(8621):1170\u20132.","journal-title":"Lancet"},{"issue":"8804","key":"9595_CR81","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/0140-6736(92)91594-X","volume":"339","author":"Z Laron","year":"1992","unstructured":"Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet. 1992;339(8804):1258\u201361.","journal-title":"Lancet"},{"issue":"3","key":"9595_CR82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1515\/JPEM.1995.8.3.149","volume":"8","author":"B Klinger","year":"1995","unstructured":"Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab. 1995;8(3):149\u201358.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"9595_CR83","first-page":"766","volume":"5","author":"Z Laron","year":"2008","unstructured":"Laron Z. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev. 2008;5(3):766\u201371.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"9595_CR84","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ghir.2005.12.001","volume":"16","author":"Z Laron","year":"2006","unstructured":"Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Hormon IGF Res. 2006;16(1):61\u20134.","journal-title":"Growth Hormon IGF Res"},{"issue":"5","key":"9595_CR85","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2265.1994.tb01829.x","volume":"41","author":"Z Laron","year":"1994","unstructured":"Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol. 1994;41(5):631\u20138.","journal-title":"Clin Endocrinol"},{"issue":"10","key":"9595_CR86","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0026-0495(96)90245-0","volume":"45","author":"Z Laron","year":"1996","unstructured":"Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism. 1996;45(10):1263\u20136.","journal-title":"Metabolism"},{"key":"9595_CR87","doi-asserted-by":"publisher","first-page":"101312","DOI":"10.1016\/j.ghir.2020.02.001","volume":"52","author":"C Barazani","year":"2020","unstructured":"Barazani C, Werner H, Laron Z. Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment - a pilot study. Growth Hormon IGF Res. 2020;52:101312.","journal-title":"Growth Hormon IGF Res"},{"issue":"4","key":"9595_CR88","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1515\/JPEM.2003.16.4.509","volume":"16","author":"B Sivan","year":"2003","unstructured":"Sivan B, Lilos P, Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab. 2003;16(4):509\u201320.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"9595_CR89","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1530\/eje.0.1380176","volume":"138","author":"Z Laron","year":"1998","unstructured":"Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol. 1998;138(2):176\u201380.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"9595_CR90","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2265.1998.00356.x","volume":"48","author":"B Klinger","year":"1998","unstructured":"Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol. 1998;48(1):81\u20137.","journal-title":"Clin Endocrinol"},{"key":"9595_CR91","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/978-3-642-11183-9_47","volume-title":"Laron syndrome from man to mouse","author":"Z Laron","year":"2011","unstructured":"Laron Z. Adverse effects encountered during IGF-I treatment of patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Berlin: Springer Verlag; 2011. p. 419\u201326."},{"issue":"1","key":"9595_CR92","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ghir.2006.10.007","volume":"17","author":"O Shevah","year":"2007","unstructured":"Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Hormon IGF Res. 2007;17(1):54\u20137.","journal-title":"Growth Hormon IGF Res"},{"key":"9595_CR93","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-10-0859","volume":"164","author":"R Steuerman","year":"2011","unstructured":"Steuerman R, Shevah O, Laron Z. Congenital IGF-I deficiency tends to confer protection against postnatal development of malignancies. Eur J Endocrinol. 2011;164:485\u20139.","journal-title":"Eur J Endocrinol"},{"key":"9595_CR94","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S0140-6736(04)16044-3","volume":"363","author":"AG Renehan","year":"2004","unstructured":"Renehan AG, Zwahlen MCM, O\u2019Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346\u201353.","journal-title":"Lancet"},{"key":"9595_CR95","doi-asserted-by":"publisher","first-page":"0ra13","DOI":"10.1126\/scitranslmed.3001845","volume":"3","author":"J Guevara-Aguirre","year":"2011","unstructured":"Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3:0ra13.","journal-title":"Sci Transl Med"},{"key":"9595_CR96","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1210\/en.2005-0607","volume":"146","author":"Z Wang","year":"2005","unstructured":"Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)\/T antigen mouse. Endocrinology. 2005;146:5188\u201396.","journal-title":"Endocrinology"},{"key":"9595_CR97","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1158\/0008-5472.CAN-07-6271","volume":"68","author":"T Moore","year":"2008","unstructured":"Moore T, Carbajal S, Beltran L, Perkins SN, Yakar S, LeRoith D, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor-I levels. Cancer Res. 2008;68:3680\u20138.","journal-title":"Cancer Res"},{"key":"9595_CR98","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/ERC-16-0054","volume":"23","author":"L Lapkina-Gendler","year":"2016","unstructured":"Lapkina-Gendler L, Rotem I, Pasmanik-Chor M, Gurwitz D, Sarfstein R, Laron Z, et al. Identification of signaling pathways associated with cancer protection in Laron syndrome. Endocr Relat Cancer. 2016;23:399\u2013410.","journal-title":"Endocr Relat Cancer"},{"key":"9595_CR99","first-page":"6","volume":"19","author":"H Werner","year":"2017","unstructured":"Werner H, Lapkina-Gendler L, Laron Z. Fifty years on: new lessons from Laron syndrome. Isr Med Assoc J. 2017;19:6\u20137.","journal-title":"Isr Med Assoc J"},{"key":"9595_CR100","first-page":"596","volume":"8","author":"H Werner","year":"2019","unstructured":"Werner H, Lapkina-Gendler L, Achlaug L, Nagaraj K, Somri L, Yaron-Saminsky D, et al. Genome-wide profiling of Laron syndrome patients identifies novel cancer protection pathways. Cells (Basel). 2019;8:596.","journal-title":"Cells (Basel)"},{"key":"9595_CR101","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1073\/pnas.1715930115","volume":"115","author":"K Nagaraj","year":"2018","unstructured":"Nagaraj K, Lapkina-Gendler L, Sarfstein R, Gurwitz D, Pasmanik-Chor M, Laron Z, et al. Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action. Proc Natl Acad Sci U S A. 2018;115:1045\u201350.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-020-09595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-020-09595-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-020-09595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:58:05Z","timestamp":1632272285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-020-09595-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["9595"],"URL":"https:\/\/doi.org\/10.1007\/s11154-020-09595-0","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]},"assertion":[{"value":"11 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Hospital Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Zvi Laron has nothing to declare.Haim Werner has nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}